Caplin Point Laboratories Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Caplin Point Laboratories kazanç ve gelirin sırasıyla yıllık 13.6% ve 13.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 13.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

13.6%

Kazanç büyüme oranı

13.6%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.7%
Gelir büyüme oranı	13.2%
Gelecekteki özkaynak getirisi	18.6%
Analist kapsamı	Low
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Recent updates

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 31

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Sep 12

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Aug 10

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Jul 12

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12

Kazanç ve Gelir Büyüme Tahminleri

NSEI:CAPLIPOINT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	25,604	7,061	5,040	5,119	1
3/31/2026	22,369	5,806	4,138	5,220	3
3/31/2025	19,665	5,069	3,174	4,027	3
9/30/2024	18,328	4,936	2,310	3,748	N/A
6/30/2024	17,577	4,776	N/A	N/A	N/A
3/31/2024	16,961	4,571	1,726	3,184	N/A
12/31/2023	16,318	4,376	N/A	N/A	N/A
9/30/2023	15,683	4,179	399	2,593	N/A
6/30/2023	15,157	3,947	N/A	N/A	N/A
3/31/2023	14,683	3,763	779	2,714	N/A
12/31/2022	14,182	3,532	N/A	N/A	N/A
9/30/2022	13,724	3,307	2,305	3,467	N/A
6/30/2022	13,153	3,140	N/A	N/A	N/A
3/31/2022	12,710	2,998	2,456	3,367	N/A
12/31/2021	12,099	2,872	N/A	N/A	N/A
9/30/2021	11,581	2,767	1,288	2,044	N/A
6/30/2021	11,217	2,586	N/A	N/A	N/A
3/31/2021	10,624	2,423	1,953	2,686	N/A
12/31/2020	9,986	2,248	N/A	N/A	N/A
9/30/2020	9,524	2,189	1,650	1,877	N/A
6/30/2020	9,107	2,193	N/A	N/A	N/A
3/31/2020	8,640	2,150	-321	447	N/A
12/31/2019	8,356	2,159	N/A	N/A	N/A
9/30/2019	7,664	2,032	-331	830	N/A
6/30/2019	6,948	1,894	N/A	N/A	N/A
3/31/2019	6,490	1,766	182	834	N/A
12/31/2018	6,048	1,621	N/A	N/A	N/A
9/30/2018	5,874	1,538	N/A	N/A	N/A
6/30/2018	5,628	1,459	N/A	N/A	N/A
3/31/2018	5,399	1,448	N/A	665	N/A
12/31/2017	5,145	1,430	N/A	N/A	N/A
9/30/2017	4,757	1,297	N/A	N/A	N/A
6/30/2017	4,401	1,165	N/A	N/A	N/A
3/31/2017	4,016	956	N/A	676	N/A
12/31/2016	3,655	783	N/A	N/A	N/A
9/30/2016	3,420	703	N/A	N/A	N/A
6/30/2016	3,238	619	N/A	N/A	N/A
3/31/2016	3,088	584	N/A	565	N/A
12/31/2015	2,906	535	N/A	N/A	N/A
9/30/2015	2,722	465	N/A	N/A	N/A
6/30/2015	2,518	410	N/A	499	N/A
3/31/2015	2,296	353	N/A	N/A	N/A
12/31/2014	2,074	318	N/A	N/A	N/A
9/30/2014	1,893	305	N/A	N/A	N/A
6/30/2014	1,731	258	N/A	598	N/A
3/31/2014	1,643	204	N/A	N/A	N/A
12/31/2013	1,517	167	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CAPLIPOINT 'nin tahmini kazanç büyümesi (yıllık 13.6% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: CAPLIPOINT şirketinin kazançlarının (yıllık 13.6% ) Indian pazarından (yıllık 18% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CAPLIPOINT şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CAPLIPOINT şirketinin gelirinin (yıllık 13.2% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CAPLIPOINT şirketinin gelirinin (yıllık 13.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CAPLIPOINT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.6 %).

Caplin Point Laboratories Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Price target increased by 14% to ₹2,142

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Price target increased by 17% to ₹1,717

Price target increased by 8.0% to ₹1,076

Price target increased to ₹948

Recent updates

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director

Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)

Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Price target increased by 14% to ₹2,142

Upcoming dividend of ₹2.50 per share

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Price target increased by 17% to ₹1,717

Dividend of ₹2.50 announced

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 18%

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 16%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations